<?xml version="1.0" encoding="UTF-8"?>
<ref id="B53">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Heuvel</surname>
    <given-names>S. A. S. v. d.</given-names>
   </name>
   <name>
    <surname>Wal</surname>
    <given-names>S. E. I. v. d.</given-names>
   </name>
   <name>
    <surname>Smedes</surname>
    <given-names>L. A.</given-names>
   </name>
   <name>
    <surname>Radema</surname>
    <given-names>S. A.</given-names>
   </name>
   <name>
    <surname>Alfen</surname>
    <given-names>N. v.</given-names>
   </name>
   <name>
    <surname>Vissers</surname>
    <given-names>K. C. P.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2017</year>). 
  <article-title>Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy</article-title>. 
  <source>Pain Res. Manag.</source>
  <volume>2017</volume>, 
  <fpage>1</fpage>â€“
  <lpage>9</lpage>. 
  <pub-id pub-id-type="doi">10.1155/2017/8053474</pub-id>
 </mixed-citation>
</ref>
